Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations

The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in recent years. Based on the efficacy results of the phase III CheckMate 067 trial, nivolumab in combination with ipilimumab is one of the first-line standard options for advanced mela...

Descripción completa

Detalles Bibliográficos
Autores principales: Vázquez-Montero, Lucía, de la Gala, María del Carmen Álamo, de la Cruz-Merino, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315455/
https://www.ncbi.nlm.nih.gov/pubmed/37404764
http://dx.doi.org/10.3389/fonc.2023.1187840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315455/
https://www.ncbi.nlm.nih.gov/pubmed/37404764
http://dx.doi.org/10.3389/fonc.2023.1187840

Ejemplares similares